{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:59:49Z","timestamp":1791251989743,"version":"4.1.0"},"reference-count":57,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG2018-21389"],"award-info":[{"award-number":["IG2018-21389"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fellowship FIRC-AIRC three-years fellowship &quot;Carlo Zanotti&quot;","award":["24107"],"award-info":[{"award-number":["24107"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Paradoxical psoriasis (PP) may occur during treatment with anti-tumor necrosis factor-alpha (TNF-\u03b1) drugs in various chronic immune-mediated diseases, mainly inflammatory bowel diseases (IBD) and psoriasis. In this study, clinical and genetic characteristics of PP arising in IBD and psoriatic patients were investigated to identify disease-specific markers of the paradoxical effect. A total of 161 IBD and psoriatic patients treated with anti-TNF-\u03b1 drugs were included in the study. Of these patients, 39 developed PP. All patients were characterized for the main clinical\u2013pathologic characteristics and genotyped for six candidate single nucleotide polymorphisms (SNPs) selected for their possible role in PP susceptibility. In IBD patients, the onset of PP was associated with female sex, presence of comorbidities, and use of adalimumab. IBD patients with PP had a higher frequency of the TNF-\u03b1 rs1799964 rare allele (p = 0.006) compared with cases without the paradoxical effect, and a lower frequency of the human leucocyte antigen (HLA)-Cw06 rs10484554 rare allele (p = 0.03) compared with psoriatic patients with PP. Overall, these findings point to specific clinical and genetic characteristics of IBD patients with PP and provide data showing that genetic variability may be related to the paradoxical effect of anti-TNF-\u03b1 drugs with possible implications into clinical practice.<\/jats:p>","DOI":"10.3390\/ijms21217873","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T02:34:54Z","timestamp":1603679694000},"page":"7873","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Paradoxical Psoriasis Induced by Anti-TNF\u03b1 Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers"],"prefix":"10.3390","volume":"21","author":[{"given":"Agostino","family":"Bucalo","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Rega","sequence":"additional","affiliation":[{"name":"Clinic of Dermatology Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4983-4420","authenticated-orcid":false,"given":"Arianna","family":"Zangrilli","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Policlinico Tor Vergata, Tor Vergata University of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0712-9379","authenticated-orcid":false,"given":"Valentina","family":"Silvestri","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Valentini","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Scafetta","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Marraffa","sequence":"additional","affiliation":[{"name":"Clinic of Dermatology Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Grassi","sequence":"additional","affiliation":[{"name":"Clinic of Dermatology Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rogante","sequence":"additional","affiliation":[{"name":"Clinic of Dermatology Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Piccolo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Policlinico Tor Vergata, Tor Vergata University of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cucchiara","sequence":"additional","affiliation":[{"name":"Pediatric Gastroenterology and Liver Unit, Maternal and Child Health Department, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca","family":"Viola","sequence":"additional","affiliation":[{"name":"Pediatric Gastroenterology and Liver Unit, Maternal and Child Health Department, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8697-6896","authenticated-orcid":false,"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Policlinico Tor Vergata, Tor Vergata University of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ottini","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Richetta","sequence":"additional","affiliation":[{"name":"Clinic of Dermatology Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000479475","article-title":"Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others","volume":"53","author":"Puig","year":"2018","journal-title":"Curr. Probl. Derm."},{"key":"ref_2","first-page":"169","article-title":"Psoriasis Induced by Anti-Tumor Necrosis Factor Alpha Agents: A Comprehensive Review of the Literature","volume":"24","author":"Ciccarelli","year":"2016","journal-title":"Acta Derm. Croat."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaad.2016.08.012","article-title":"Tumor Necrosis Factor-\u03b1 Inhibitor-Induced Psoriasis: Systematic Review of Clinical Features, Histopathological Findings, and Management Experience","volume":"76","author":"Brown","year":"2016","journal-title":"J. Am. Acad. Derm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/art.23835","article-title":"Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: A Literature Review and Potential Mechanisms of Action","volume":"59","author":"Collamer","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2133.2004.06107.x","article-title":"Psoriatic lesions induced by anti-tumour necrosis factor-alpha treatment: Two cases","volume":"151","author":"Dereure","year":"2004","journal-title":"Br. J. Derm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1007\/s10620-015-3763-0","article-title":"Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease","volume":"60","author":"George","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.crohns.2012.08.007","article-title":"Induction or Exacerbation of Psoriatic Lesions during Anti-TNF-\u03b1 Therapy for Inflammatory Bowel Disease: A Systematic Literature Review Based on 222 Cases","volume":"7","author":"Denadai","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1365-2036.2011.04866.x","article-title":"Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: A new series and a review of 120 cases from the literature","volume":"34","author":"Cullen","year":"2011","journal-title":"Aliment. Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.13352","article-title":"Paradoxical Psoriasis in a Large Cohort of Patients with Inflammatory Bowel Disease Receiving Treatment with Anti-TNF Alpha: 5-Year Follow-up Study","volume":"42","author":"Pugliese","year":"2015","journal-title":"Aliment. Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2010.07.022","article-title":"Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy","volume":"8","author":"Rahier","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/MIB.0000000000000757","article-title":"Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study","volume":"22","author":"Guerra","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_12","first-page":"2831","article-title":"Development of Psoriasis Scalp with Alopecia during Treatment of Crohn\u2019s Disease with Infliximab and Rapid Response to Both Diseases to Ustekinumab","volume":"17","author":"Andrisani","year":"2013","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"key":"ref_13","first-page":"1175","article-title":"Tumor necrosis factor inhibitors\u2014State of knowledge","volume":"10","author":"Lis","year":"2013","journal-title":"Arch. Med. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjd.12425","article-title":"The Relationship between Tumour Necrosis Factor (TNF)-\u03b1 Promoter and IL12B\/IL-23R Genes Polymorphisms and the Efficacy of Anti-TNF-\u03b1 Therapy in Psoriasis: A Case-Control Study","volume":"169","author":"Gallo","year":"2013","journal-title":"Br. J. Derm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3389\/fphar.2019.00671","article-title":"Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor","volume":"10","author":"Pagnini","year":"2019","journal-title":"Front. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/ijd.14072","article-title":"Clinical Management of Anti-TNF-Alpha-Induced Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients: A Systematic Review","volume":"57","author":"Melo","year":"2018","journal-title":"Int. J. Derm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nrgastro.2012.125","article-title":"Paradoxical Inflammation Induced by Anti-TNF Agents in Patients with IBD","volume":"9","author":"Cleynen","year":"2012","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/apt.14822","article-title":"Incidence of Psoriasiform Diseases Secondary to Tumour Necrosis Factor Antagonists in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study","volume":"48","author":"Bae","year":"2018","journal-title":"Aliment. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard.62.9.829","article-title":"Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: A new perspective on the role of host defence in the pathogenesis of the disease?","volume":"62","author":"Baeten","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/art.21233","article-title":"Psoriasis induced by anti-tumor necrosis factor therapy: A paradoxical adverse reaction","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_21","first-page":"380","article-title":"Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: A case series","volume":"34","author":"Cohen","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_22","first-page":"223","article-title":"Psoriasis and pustular dermatitis triggered by TNF- {alpha} inhibitors in patients with rheumatologic conditions","volume":"143","author":"Ghoreishi","year":"2007","journal-title":"Arch. Derm."},{"key":"ref_23","first-page":"336","article-title":"Paradoxical Psoriasiform Reactions to Anti-TNF\u03b1 Drugs Are Associated with Genetic Polymorphisms in Patients with Psoriasis","volume":"16","author":"Cabaleiro","year":"2015","journal-title":"Pharm. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/09546630802441234","article-title":"Induction and exarcerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases","volume":"20","author":"Ko","year":"2009","journal-title":"J. Dermatol. Treat."},{"key":"ref_25","first-page":"33089-5","article-title":"TNF-\u03b1 Inhibitor-Induced psoriasis: A decade of experience at the Cleveland Clinic","volume":"S0190-9622","author":"Mazloom","year":"2018","journal-title":"J. Am. Acad. Derm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/apt.13542","article-title":"Genetic basis of TNF-\u03b1 antagonist associated psoriasis in inflammatory bowel diseases: A genotype-phenotype analysis","volume":"43","author":"Vedak","year":"2016","journal-title":"Aliment. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1097\/MIB.0000000000001169","article-title":"Prevalence and Phenotype of Concurrent Psoriasis and Inflammatory Bowel Disease","volume":"23","author":"Eppinga","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaad.2020.01.006","article-title":"Histologic comparison of tumor necrosis factor-\u03b1 inhibitor-induced psoriasis and psoriasis vulgaris","volume":"83","author":"Hu","year":"2020","journal-title":"J. Am. Acad. Derm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.3389\/fimmu.2018.02746","article-title":"Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon","volume":"9","author":"Mylonas","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF Blockade Induces a Dysregulated Type I Interferon Response without Autoimmunity in Paradoxical Psoriasis","volume":"9","author":"Conrad","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_31","first-page":"31180-4","article-title":"Family history of psoriasis, psychological stressors, and tobacco use are associated with the development of tumor necrosis factor-\u03b1 inhibitor-induced psoriasis: A case-control study","volume":"S0190-9622","author":"Ya","year":"2020","journal-title":"J. Am. Acad. Derm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/MPG.0b013e31828390ba","article-title":"Infliximab-Induced Psoriasis and Psoriasiform Skin Lesions in Pediatric Crohn Disease and a Potential Association with IL-23 Receptor Polymorphisms","volume":"56","author":"Sherlock","year":"2013","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Di Meglio, P., Di Cesare, A., Laggner, U., Chu, C.C., Napolitano, L., Villanova, F., Tosi, I., Capon, F., Trembath, R.C., and Peris, K. (2011). The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017160"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1046\/j.1523-1747.1999.00724.x","article-title":"HLA-Cw6 and the Genetic Predisposition to Psoriasis: A Meta-Analysis of Published Serologic Studies","volume":"113","author":"Mallon","year":"1999","journal-title":"J. Invest. Derm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3109\/08916934.2013.796937","article-title":"Association of IFIH1 Rs1990760 Polymorphism with Susceptibility to Autoimmune Diseases: A Meta-Analysis","volume":"46","author":"Cen","year":"2013","journal-title":"Autoimmunity"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1744-313X.2011.01068.x","article-title":"Genetic Variants in IFIH1 Play Opposite Roles in the Pathogenesis of Psoriasis and Chronic Periodontitis: Genetic Variants in IFIH1","volume":"39","author":"Chen","year":"2012","journal-title":"Int. J. Immunogenet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2217\/pgs.15.90","article-title":"Association between TNF-\u03b1 (-308 A\/G, -238 A\/G, -857 C\/T) Polymorphisms and Responsiveness to TNF-\u03b1 Blockers in Spondyloarthropathy, Psoriasis and Crohn\u2019s Disease: A Meta-Analysis","volume":"16","author":"Song","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3892\/br.2017.908","article-title":"Evaluation of Tumor Necrosis Factor (TNF)-\u03b1 MRNA Expression Level and the Rs1799964 Polymorphism of the TNF-\u03b1 Gene in Peripheral Mononuclear Cells of Patients with Inflammatory Bowel Diseases","volume":"6","author":"Nourian","year":"2017","journal-title":"Biomed. Rep."},{"key":"ref_39","first-page":"379","article-title":"Anti-tnf\u03b1 antibody induced psoriasiform skin lesions in patients with inflammatory bowel disease: An irish cohort study","volume":"110","author":"Kirthi","year":"2017","journal-title":"QJM"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/pde.13081","article-title":"Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents","volume":"34","author":"Eickstaedt","year":"2017","journal-title":"Pediatr. Derm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1038\/ajg.2009.372","article-title":"Efficacy of adalimumab in moderate-to-severe pediatric Crohn\u2019s disease","volume":"104","author":"Viola","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/MPG.0b013e3181f3d9ab","article-title":"Infliximab-induced psoriasis in children with inflammatory bowel disease","volume":"52","author":"Hiremath","year":"2011","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/ibd.20450","article-title":"Guttate psoriasis induced by infliximab in a child with Crohn\u2019s disease","volume":"14","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1525-1470.2011.01521.x","article-title":"Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children","volume":"29","author":"Perman","year":"2012","journal-title":"Pediatr. Derm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/MPG.0000000000000276","article-title":"Biological Therapy in a Pediatric Crohn Disease Population at a Referral Center","volume":"58","author":"Nuti","year":"2014","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40257-017-0322-9","article-title":"Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis","volume":"19","author":"Reolid","year":"2018","journal-title":"Am. J. Clin. Derm."},{"key":"ref_47","first-page":"e12729","article-title":"Paradoxical Case Effects of Psoriasis Following Adalimumab Therapy: A Case Series","volume":"31","author":"Zangrilli","year":"2018","journal-title":"Dermatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1007\/s10620-018-5096-2","article-title":"Stricturing and Fistulizing Crohn\u2019s Disease Is Associated with Anti-Tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease","volume":"63","author":"Weizman","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1002\/ibd.21643","article-title":"Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: Experience from a consecutive cohort of inflammatory bowel disease patients","volume":"17","author":"Baumgart","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/jgh.14034","article-title":"Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn\u2019s disease","volume":"33","author":"Tanaka","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1684\/ejd.2010.0946","article-title":"Morphea, an unusual side effect of anti-TNF-alpha treatment","volume":"20","author":"Mattozzi","year":"2010","journal-title":"Eur. J. Derm."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.gene.2018.09.042","article-title":"Genomic Alterations Driving Psoriasis Pathogenesis","volume":"683","author":"Singh","year":"2019","journal-title":"Gene"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/MIB.0000000000000088","article-title":"Skin reactions during anti-TNF\u03b1 therapy for pediatric inflammatory bowel disease: A 2-year prospective study","volume":"20","author":"Heiskanen","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.ad.2017.07.002","article-title":"Moderate Psoriasis: A Proposed Definition","volume":"108","author":"Notario","year":"2017","journal-title":"Actas Dermosifiliogr."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3109\/1547691X.2015.1115448","article-title":"Protective Role of R381Q (Rs11209026) Polymorphism in IL-23R Gene in Immune-Mediated Diseases: A Comprehensive Review","volume":"13","author":"Abdollahi","year":"2016","journal-title":"J. Immunotoxicol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"18584","DOI":"10.1038\/srep18584","article-title":"Association of Interleukin-23 receptor gene polymorphisms with susceptibility to Crohn\u2019s disease: A meta-analysis","volume":"5","author":"Xu","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.18632\/oncotarget.13607","article-title":"IL-23R Mutation Is Associated with Ulcerative Colitis: A Systemic Review and Meta-Analysis","volume":"8","author":"Peng","year":"2017","journal-title":"Oncotarget"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/21\/7873\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:27:10Z","timestamp":1760178430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/21\/7873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":57,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["ijms21217873"],"URL":"https:\/\/doi.org\/10.3390\/ijms21217873","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,23]]}}}